{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:54:56Z","timestamp":1774634096317,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-025-01192-y","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:22:07Z","timestamp":1769617327000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options\u2014A Podcast"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-9168","authenticated-orcid":false,"given":"Eric K.","family":"Singhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-9247","authenticated-orcid":false,"given":"Eric S.","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"4","key":"1192_CR1","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013;20(4):e300\u20136. https:\/\/doi.org\/10.3747\/co.20.1481.","journal-title":"Curr Oncol"},{"issue":"15","key":"1192_CR2","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1158\/1078-0432.Ccr-13-0318","volume":"19","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0318.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.24181","volume":"115","author":"DW Wong","year":"2009","unstructured":"Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723\u201333. https:\/\/doi.org\/10.1002\/cncr.24181.","journal-title":"Cancer"},{"issue":"13","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.Ccr-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275\u201383. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-0168.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1192_CR5","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1002\/cncr.27409","volume":"118","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502\u201311. https:\/\/doi.org\/10.1002\/cncr.27409.","journal-title":"Cancer"},{"issue":"2","key":"1192_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.rmed.2013.11.020","volume":"108","author":"HJ Kang","year":"2014","unstructured":"Kang HJ, Lim HJ, Park JS, et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med. 2014;108(2):388\u201394. https:\/\/doi.org\/10.1016\/j.rmed.2013.11.020.","journal-title":"Respir Med"},{"issue":"6","key":"1192_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.Cd-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714\u201329. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1256.","journal-title":"Cancer Discov"},{"issue":"suppl 4","key":"1192_CR8","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"10","key":"1192_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","volume":"13","author":"A Drilon","year":"2018","unstructured":"Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13(10):1595\u2013601. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.004.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1192_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","volume":"18","author":"CS Gillespie","year":"2023","unstructured":"Gillespie CS, Mustafa MA, Richardson GE, et al. Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis. J Thorac Oncol. 2023;18(12):1703\u201313. https:\/\/doi.org\/10.1016\/j.jtho.2023.06.017.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1192_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108\u201311. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.020.","journal-title":"Lung Cancer"},{"issue":"21","key":"1192_CR12","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1810171.","journal-title":"N Engl J Med"},{"issue":"11","key":"1192_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):1617\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3523.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1192_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"21","key":"1192_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2027187.","journal-title":"N Engl J Med"},{"key":"1192_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105931","volume":"174","author":"B Zhao","year":"2021","unstructured":"Zhao B, Han Y, Wang Y, et al. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. Pharmacol Res. 2021;174:105931. https:\/\/doi.org\/10.1016\/j.phrs.2021.105931.","journal-title":"Pharmacol Res"},{"key":"1192_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108436","volume":"201","author":"D Uprety","year":"2025","unstructured":"Uprety D, Abrahami D, Marcum ZA, et al. Brain metastases and mortality in patients with ALK\u00a0+\u00a0metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: an observational cohort study. Lung Cancer. 2025;201:108436. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108436.","journal-title":"Lung Cancer"},{"issue":"8","key":"1192_CR18","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1007\/s12325-024-02899-6","volume":"41","author":"K Arnaoutakis","year":"2024","unstructured":"Arnaoutakis K, Wan Y, Elliott J, et al. Real-world treatment patterns and outcomes across three lines of therapy in patients with ALK+ NSCLC. Adv Ther. 2024;41(8):3217\u201331. https:\/\/doi.org\/10.1007\/s12325-024-02899-6.","journal-title":"Adv Ther"},{"key":"1192_CR19","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.1.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"11","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720\u201344. https:\/\/doi.org\/10.1021\/jm500261q.","journal-title":"J Med Chem"},{"issue":"12","key":"1192_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091\u2013108. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.035.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"1192_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.478.","journal-title":"Ann Oncol"},{"key":"1192_CR23","unstructured":"Alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC). [press release]. November 6 2017."},{"key":"1192_CR24","unstructured":"FDA approves brigatinib for ALK-positive metastatic NSCLC. [press release]. May 22 2020."},{"key":"1192_CR25","unstructured":"FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer [press release]. December 18 2024."},{"issue":"1","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","volume":"37","author":"S Peters","year":"2026","unstructured":"Peters S, Camidge R, Dziadziuszko R, et al. Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study. Ann Oncol. 2026;37(1):92\u2013103.\u00a0https:\/\/doi.org\/10.1016\/j.annonc.2025.09.018.","journal-title":"Ann Oncol"},{"key":"1192_CR27","unstructured":"Ensacove (ensartinib). Package insert. Xcovery Holdings, Inc; 2024."},{"issue":"4","key":"1192_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/s2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354\u201366. https:\/\/doi.org\/10.1016\/s2213-2600(22)00437-4.","journal-title":"Lancet Respir Med"},{"issue":"29","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/jco.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024;42(29):3400\u20139. https:\/\/doi.org\/10.1200\/jco.24.00581.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","volume":"14","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib\u00a0in\u00a0untreated ALK-positive advanced non-small cell\u00a0lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233\u201343. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.007.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1192_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf287","volume":"30","author":"G Liu","year":"2025","unstructured":"Liu G, Solomon BJ, Mazieres J, Kim D-W, Cortinovis D, Inoue T, et al. Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. Oncologist. 2025;30(10):oyaf287. https:\/\/doi.org\/10.1093\/oncolo\/oyaf287.","journal-title":"Oncologist"},{"key":"1192_CR32","doi-asserted-by":"publisher","unstructured":"Liu G, Nadal E, Baijal S, et al. Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study. J Clin Oncol. 2025;43(suppl 16):Abstract 8590. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8590","DOI":"10.1200\/JCO.2025.43.16_suppl.8590"},{"key":"1192_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107919","volume":"195","author":"JR Bauman","year":"2024","unstructured":"Bauman JR, Liu G, Preeshagul I, et al. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. Lung Cancer. 2024;195:107919. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107919.","journal-title":"Lung Cancer"},{"issue":"6","key":"1192_CR34","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409\u201316. https:\/\/doi.org\/10.1093\/annonc\/mdy121.","journal-title":"Ann Oncol"},{"issue":"12","key":"1192_CR35","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1192_CR36","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.jtho.2024.09.134","volume":"19","author":"T Mok","year":"2024","unstructured":"Mok T, Solomon BJ, Campelo MRG, et al. MA06.07 patterns of progression with lorlatinib and insights into subsequent anticancer therapy efficacy in advanced ALK+ NSCLC. J Thorac Oncol. 2024;19(10):S75. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.134.","journal-title":"J Thorac Oncol"},{"key":"1192_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","volume":"139","author":"K Nakagawa","year":"2020","unstructured":"Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020;139:195\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2019.11.025.","journal-title":"Lung Cancer"},{"key":"1192_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26135969","author":"EM Urbanska","year":"2025","unstructured":"Urbanska EM, Koffeldt PR, Grauslund M, Melchior LC, S\u00f8rensen JB, Santoni-Rugiu E. Refining criteria for choosing the first-line treatment for real-world patients with advanced ALK-rearranged NSCLC. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26135969.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1192_CR39","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S1556-0864(25)00289-8","volume":"20","author":"J Mazieres","year":"2025","unstructured":"Mazieres J, Bauer T, Abrahami D, et al. 94P: Long-term efficacy of lorlatinib vs alectinib in patients with and without brain\/central nervous system metastases: matching-adjusted indirect comparisons. J Thorac Oncol. 2025;20(3):S67\u20138. https:\/\/doi.org\/10.1016\/S1556-0864(25)00289-8.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1192_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.21037\/tlcr-22-656","volume":"12","author":"G Chazan","year":"2023","unstructured":"Chazan G, Solomon BJ. Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer\u2014a narrative review. Transl Lung Cancer Res. 2023;12(2):369\u201378. https:\/\/doi.org\/10.21037\/tlcr-22-656.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"1192_CR41","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","volume":"37","author":"M Reed","year":"2020","unstructured":"Reed M, Rosales AS, Chioda MD, Parker L, Devgan G, Kettle J. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv Ther. 2020;37(6):3019\u201330. https:\/\/doi.org\/10.1007\/s12325-020-01365-3.","journal-title":"Adv Ther"},{"issue":"2","key":"1192_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/jco.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34(2):123\u20139. https:\/\/doi.org\/10.1200\/jco.2015.62.0138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1192_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101191","volume":"14","author":"SI Ou","year":"2021","unstructured":"Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. Will the clinical development of 4th-generation \u201cdouble mutant active\u201d ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021;14(11):101191. https:\/\/doi.org\/10.1016\/j.tranon.2021.101191.","journal-title":"Transl Oncol"},{"issue":"9","key":"1192_CR44","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1535-7163.Mct-21-0221","volume":"20","author":"BW Murray","year":"2021","unstructured":"Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1499\u2013507. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0221.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1192_CR45","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1158\/2159-8290.Cd-24-0231","volume":"14","author":"JJ Lin","year":"2024","unstructured":"Lin JJ, Horan JC, Tangpeerachaikul A, et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 2024;14(12):2367\u201386. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0231.","journal-title":"Cancer Discov"},{"key":"1192_CR46","unstructured":"ClinicalTrials.gov. A study of NVL-655 in patients with advanced NSCLC and other solid tumors harboring ALK rearrangement or activating ALK mutation (ALKOVE-1). https:\/\/clinicaltrials.gov\/study\/NCT05384626. Accessed 20 March 2025."},{"key":"1192_CR47","unstructured":"ClinicalTrials.gov. Neladalkib (NVL-655) for TKI-naive patients with advanced ALK-positive NSCLC (ALKAZAR). https:\/\/www.clinicaltrials.gov\/study\/NCT06765109. Accessed 7 April 2025."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01192-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:46Z","timestamp":1774630666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01192-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01192-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version, the placement of the\npodcast video is moved between key points and the main text.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Decdlarations"}},{"value":"This podcast was supported by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors received no honoraria related to the development of this publication. Eric K. Singhi reports consulting and\/or serving on advisory boards with Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Nuvation Bio, and Regeneron and research funding from Rexanna\u2019s Foundation for Fighting Lung Cancer. Eric S. Nadler reports consulting, speaking, and\/or serving on advisory boards with Amgen, AstraZeneca, Bristol Myers Squibb, Catalyst, EMD Serono, Merck, Novocure, Nuvation, and Regeneron.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval, Consent to Participate, Consent to publish, Data Availability, Code Availability"}},{"value":"Eric K. Singhi and Eric S. Nadler made substantial contributions to the development of the podcast, critically reviewed and revised the podcast, and provided final approval of the podcast as submitted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}